AtriCure Stock News

Shares of AtriCure Inc. (NASDAQ:ATRC) gapped down before the market opened on Wednesday . The stock had previously closed at $40.02, but opened at $36.41. AtriCure shares last traded at $36.11, with a

AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedur

Stifel Financial Corp cut its position in AtriCure Inc. (NASDAQ:ATRC) by 34.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis

Captrust Financial Advisors acquired a new stake in AtriCure Inc. (NASDAQ:ATRC) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 4,500 shares

First Republic Investment Management Inc. acquired a new position in shares of AtriCure Inc. (NASDAQ:ATRC) during the second quarter, Holdings Channel reports. The fund acquired 5,181 shares of the me

Equities analysts expect AtriCure Inc. (NASDAQ:ATRC) to announce $48.16 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for AtriCure’s earnings, with the h

AtriCure has been a steady revenue growth play in medtech. Troublesome is that the business has been losing money since the IPO fifteen years ago, although the burn rate is manageable and is ''finance

Repare Therapeutics (NASDAQ:PYPD) and AtriCure (NASDAQ:ATRC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of th

Trexquant Investment LP acquired a new position in shares of AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange C

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the pos

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced

Envestnet Asset Management Inc. purchased a new stake in AtriCure Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional inve

Wall Street brokerages forecast that AtriCure Inc. (NASDAQ:ATRC) will report sales of $49.76 million for the current quarter, according to Zacks. Five analysts have provided estimates for AtriCure’s

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest